Home Newsfeeds Scotiabank Downgrades ConocoPhillips to Sector Perform, Announces $140 Price Target

Scotiabank Downgrades ConocoPhillips to Sector Perform, Announces $140 Price Target

Scotiabank analyst Paul Cheng downgrades ConocoPhillips (NYSE:COP) from Sector Outperform to Sector Perform and announces $140 price target.

byBenzinga Newsdesk

January 17, 2023

1 minute read

Scotiabank analyst Paul Cheng downgrades ConocoPhillips (NYSE:COP) from Sector Outperform to Sector Perform and announces $140 price target.

More Savings, No Disruptions: Canadian Weed Co. Makes Strategic Move To Boost Operations

By Jelena Martinovic

October 20, 9:42 AM

SNDL Inc. (NASDAQ: SNDL) announced additional optimizations of its facility footprint on Thursday to boost its cannabis operations segment.

SNDL

Gensler’s ‘SEC Twitter Account Was Compromised’ Tweet Is Now An Ordinal ‘Immortalized On Bitcoin Forever’

By Mehab Qureshi

January 10, 1:43 AM

The Bitcoin (CRYPTO: BTC) community was abuzz following a compromised tweet from the Securities and Exchange Commission’s (SEC) X account, which falsely

BTC

Analyst Ratings

Analyst Ratings for Amkor Tech

By Benzinga Insights

December 12, 12:00 PM

Analysts have provided the following ratings for Amkor Tech (NASDAQ:AMKR) within the last quarter: Bullish Somewhat Bullish Indifferent…

AMKR

Phibro Animal Health Q4 Adj. EPS $0.36 Misses $0.38 Estimate, Sales $255.30M Beat $246.02M Estimate

By Michael Horton

August 24, 4:57 PM

Phibro Animal Health (NASDAQ:PAHC) reported quarterly earnings of $0.36 per share which missed the analyst consensus estimate of $0.38 by 5.26 percent. This is a 12.5 percent increase over earnings of $0.32 per share

PAHC

Scotiabank Downgrades ConocoPhillips to Sector Perform, Announces $140 Price Target

Related Posts

More Savings, No Disruptions: Canadian Weed Co. Makes Strategic Move To Boost Operations

Gensler’s ‘SEC Twitter Account Was Compromised’ Tweet Is Now An Ordinal ‘Immortalized On Bitcoin Forever’

Analyst Ratings for Amkor Tech

Phibro Animal Health Q4 Adj. EPS $0.36 Misses $0.38 Estimate, Sales $255.30M Beat $246.02M Estimate